Overview
This clinical study aims to be used to implement and validate the AIDA tool in two phases:
- Phase 1: Risk stratification and personalised recommendations & Model development
- Phase 2: Mechanistic Model (Bioresource) development & testing
Description
The AIDA objective (project) is to develop and validate a multidisciplinary AI-powered assistant that helps clinicians diagnose precancerous inflammation, suggests personalised therapeutic strategies for medical treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This prospective clinical study aims to implement and validate such tool.
Eligibility
Inclusion Criteria:
- Subjects ≥ 18 years old with a diagnosis of GIM or previous or current H. pylori infection, to whom a gastroscopy is indicated within clinical care
- Availability of a signed informed consent form to participate in the study
Exclusion Criteria:
- Patients to whom an endoscopy is performed for the follow-up of another illness such as oesophageal varices and/or for therapy such as endoscopic dilation, feeding tube placement or endoscopic resection
- Subjects with a clinical diagnosis of gastric diseases other than GIM or GC
- Patients who have received antimicrobials during the four weeks prior to the endoscopy
- Patients who have received proton pump inhibitors and/or bismuth-based treatments at least two weeks prior to the endoscopy
- Subjects for whom clinical data are not available: H. pylori status, eradication treatment, sex, age, tobacco smoking, and first-degree family history of gastric cancer
- Subjects who lack the mental capacity to understand the nature and requirements of the study and who lack the ability to give informed consent